Company intelligence / Profile preview

Jaya Biosciences

South San Francisco, California, United States

Ownership: Private
Development stage: Preclinical

Overview

Jaya Biosciences has presented promising preclinical data demonstrating that CNS-directed AAV-mediated gene therapy can complement haploinsufficiency of lysosomal genes such as PPT1 in animal models of Alzheimer’s disease. Their lead program, JB111, has shown strong proof-of-concept efficacy in preclinical studies and is positioned for IND-enabling work with the goal to enter clinical trials within three years if funding is secured[2][3].

Therapeutic areas: Neurology
Modalities: Gene therapies (AAV-mediated gene therapy)Recombinant proteins (historical expertise)
Industry: Biotech

Drug pipeline

1 asset

JB111

Pre-clinical

Indications: PPT1-associated Alzheimer's disease

Beyond the preview

Go deeper on Jaya Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jaya Biosciences.

Explore the full profile